Fullman Nancy, Correa Gustavo C, Ikilezi Gloria, Phillips David E, Reynolds Heidi W
Exemplars in Global Health, Gates Ventures, 2401 Elliott Ave, Seattle, WA 98121, USA.
Gavi, the Vaccine Alliance, Chemin du Pommier 40, Le Grand-Saconnex, 1218 Geneva, Switzerland.
Vaccines (Basel). 2023 Mar 14;11(3):647. doi: 10.3390/vaccines11030647.
Understanding past successes in reaching unvaccinated or "zero-dose" children can help inform strategies for improving childhood immunization in other settings. Drawing from positive outlier methods, we developed a novel approach for identifying potential exemplars in reducing zero-dose children.
Focusing on 2000-2019, we assessed changes in the percentage of under-one children with no doses of the diphtheria-tetanus-pertussis vaccine (no-DTP) across two geographic dimensions in 56 low- or lower-middle-income countries: (1) national levels; (2) subnational gaps, as defined as the difference between the 5th and 95th percentiles of no-DTP prevalence across second administrative units. Countries with the largest reductions for both metrics were considered positive outliers or potential 'exemplars', demonstrating exception progress in reducing national no-DTP prevalence and subnational inequalities. Last, so-called "neighborhood analyses" were conducted for the Gavi Learning Hub countries (Nigeria, Mali, Uganda, and Bangladesh), comparing them with countries that had similar no-DTP measures in 2000 but different trajectories through 2019.
From 2000 to 2019, the Democratic Republic of the Congo, Ethiopia, and India had the largest absolute decreases for the two no-DTP dimensions-national prevalence and subnational gaps-while Bangladesh and Burundi registered the largest relative reductions for each no-DTP metric. Neighborhood analyses highlighted possible opportunities for cross-country learning among Gavi Learning Hub countries and potential exemplars in reducing zero-dose children.
Identifying where exceptional progress has occurred is the first step toward better understanding how such gains could be achieved elsewhere. Further examination of how countries have successfully reduced levels of zero-dose children-especially across variable contexts and different drivers of inequality-could support faster, sustainable advances toward greater vaccination equity worldwide.
了解过去在覆盖未接种疫苗或“零剂次”儿童方面取得的成功经验,有助于为其他地区改善儿童免疫策略提供参考。基于正异常值方法,我们开发了一种识别减少零剂次儿童潜在典范的新方法。
聚焦于2000年至2019年,我们评估了56个低收入或中低收入国家两个地理维度下一岁以下未接种白喉-破伤风-百日咳疫苗(无DTP)儿童百分比的变化:(1)国家层面;(2)次国家层面差距,定义为第二行政单位无DTP流行率第5百分位数与第95百分位数之间的差异。两个指标降幅最大的国家被视为正异常值或潜在“典范”,表明在降低国家无DTP流行率和次国家层面不平等方面取得了突出进展。最后,对全球疫苗免疫联盟学习中心国家(尼日利亚、马里、乌干达和孟加拉国)进行了所谓的“邻域分析”,将它们与2000年无DTP情况相似但2019年轨迹不同的国家进行比较。
2000年至2019年,刚果民主共和国、埃塞俄比亚和印度在国家流行率和次国家层面差距这两个无DTP维度上的绝对降幅最大,而孟加拉国和布隆迪在每个无DTP指标上的相对降幅最大。邻域分析突出了全球疫苗免疫联盟学习中心国家之间跨国学习的可能机会以及减少零剂次儿童方面的潜在典范。
确定在哪些地方取得了突出进展是更好地理解如何在其他地方取得类似成果的第一步。进一步研究各国如何成功降低零剂次儿童水平,特别是在不同背景和不平等驱动因素各异的情况下,有助于在全球范围内更快、可持续地朝着实现更大的疫苗接种公平迈进。